Mild cognitive impairment
Conditions
Interventions
Placebo food not containing curcumin. Take 90 mg of 1 capsule at a time, 1 capsule twice a day. Treatment duration will be 24 weeks.
Highly absorbable curcumin. Take 90 mg of 1 capsule at a time,
Sponsors
National Hospital Organization Kyoto Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Main selection criteria "People who are worried about forgetting things" will be recruited through posters or websites, and MMSE-J and SDS (Self-rating depression scale) interview tests will be conducted. (1) MMSE-J: 24 points or more, 27 points or less (mild cognitive impairment suspected) (2) Depression screening test SDS: 23 points or more, 47 points or less (normal range) (3) Age 50 and over, regardless of gender. (4) Obtain document consent by the person's free will If a person who is taking an oral medication other than dementia, such as a lifestyle-related disease, applies, it is possible to register after confirming that the patient is active and the condition is stable. Definition of activity: ECOG PS (Performance Status): 0 or 1 Definition of state stable: (iii) No change in the content and amount of oral medication for 6 months before the consent date (iv) No history of hospitalization within 1 year before the date of consent
Exclusion criteria
Exclusion criteria: Exclusion criteria Participants who conform to any of the following categories will be excluded from the present study. 1)Participants regularly consuming other curcumin containing health food products 2)Participants with a history of curcumin allergy 3)Participants who are pregnant or breastfeeding 4)Participants receiving medication and outpatient care for dementia 5)Participants receiving chemotherapy for a malignant tumor 6)Participants with regular use of antibiotics or steroids 7)Participants receiving two or more antiplatelet agents, or one antiplatelet agent and another antithrombotic agent (e.g., anticoagulant, EPA agent, prostacyclin agent) 8)Participants with a history of cerebral hemorrhage and taking an antiplatelet drug 9)Participants receiving oxygen therapy at home 10)Participants who have renal failure and are receiving dialysis 11)Participants with severe liver dysfunction or cirrhosis 12)Participants with severe cardiac dysfunction 13)Participants deemed inappropriate for participation in the study by the principal investigator and the sub-investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the efficacy of a newly developed high-absorption curcumin product (brand name: CurcuRouge) administered via an oral route on the general public suspected of having MCI without dementia using MMSE-J (a questionnaire for cognitive function test conducted by an interviewer) scores. | — |
Countries
Japan
Contacts
Public ContactKoji Hasegawa
National Hospital Organization Kyoto Medical Center Division of Translational Research
Outcome results
None listed